Western Europe Offers Poor Prospects To Investors In Gastrointestinal Drugs

Global Gastrointestinal Market By Region

LONDON, GREATER LONDON, UK, October 21, 2017 /EINPresswire.com/ — The global market for the drugs category that includes antacids and antiemetics is worth nearly $60 billion and is growing at 4.5% a year; this would be higher if it were not that the Western European region, one of the larger drug markets, is barely growing at all, and in fact has recently been shrinking. These trends leave the Western European market third in terms of size, worth not much more than half that of North America, and 5 percentage points behind that of Asia Pacific.
The global market for this category of drugs accounts for about 6% of the global pharma market as a whole.
The gastrointestinal diseases drugs market covers medicines used for the treatment of ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal drugs include anti-peptic agents (antacids, antagonists, proton pump inhibitors, sucralfate, and misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and stimulant/irritants.
Many of these drugs can be bought without prescription in pharmacies or supermarkets and convenience stores. This widespread availability and often low unit price are factors that boost the market in poorer regions or poor areas of rich regions like North America, which includes Mexico. In Western Europe, however, a trend to avoid over-consumption of drugs has set in and alternative therapies have become popular for those of these conditions which are not generally life-threatening.
The market for gastrointestinal drugs is quite fragmented, with above 70% shared among the many small companies outside the leading 7 and only one company, Japan’s Takeda Pharmaceuticals, having a market share that approaches 10%. The second and third largest companies in the market are Allergan of the USA and the Danish Novo Nordisk, each with shares a little over 5% of the total.
One of the trends shaping the market is an increase in R&D activities. Growing R&D activities for the development of new drugs in the treatment of gastrointestinal diseases is an emerging trend in the market. Some of the major gastrointestinal pipeline products include Perjeta (Roche), Keytruda (Merck), TAS-118 (Taiho Pharmaceutical), NeuVax (Galena Biopharma), Ipatasertib (Genentech), Durvalumab (AstraZeneca) and Napabucasin (Boston Biomedical). Technological advancements in the treatment of gastrointestinal diseases are expected to boost the market during the forecast period.

Where to Learn More
Read Gastrointestinal Drugs Market Global Report 2017 from The Business Research Company for information on the following:
Markets Covered: Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity Drugs, Antiemetics And Antinauseants, Antidiarrhoeals
Companies Mentioned: AbbVie, Johnson & Johnson, Takeda Pharmaceticals, Allergan, and UCB
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

About The Business Research Company
Visit TheBusinesResearchCompany.com. The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has research professionals at its office in the UK, India, and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. The Business Research Company’s management have more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world’s largest organizations. The Business Research Company’s Consultant have master’s qualifications from top institutes and include MBAs, MSCs, CFAs and CAs. The Business Research Company’s Consultants gain training and qualifications from the market Research Society and are trained in advanced research practices, techniques, and ethics.

Oliver Guirdham
The Business Research Company
+44 744 3439350
email us here

This Article Was Originally Posted at www.einnews.com

https://www.einnews.com/pr_news/409987374/western-europe-offers-poor-prospects-to-investors-in-gastrointestinal-drugs?ref=rss&ecode=N1bP1tH84JZ33sYs

Florida Country Music Scene

Everything Country Music in the Great State of Florida

Western Europe Offers Poor Prospects To Investors In Gastrointestinal Drugs